In Vivo Imaging in Pharmaceutical Development and Its Impact on the 3Rs
| Autor: | Barry R Campbell, Catherine D. G. Hines, Jeffrey L. Evelhoch, Weisheng Zhang, Manishkumar Patel, Wenping Li, Dinko Gonzalez Trotter |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Animal Use Alternatives Diagnostic Imaging medicine.medical_specialty Treatment response drug safety General Biochemistry Genetics and Molecular Biology Article Imaging modalities 3Rs 03 medical and health sciences Biopharmaceutical industry medicine Animals Humans Intensive care medicine business.industry target engagement Research Target engagement imaging treatment response General Medicine Longitudinal imaging drug development 030104 developmental biology Biopharmaceutical Drug development Models Animal Animal Science and Zoology business Preclinical imaging Biomarkers mechanism of action |
| Zdroj: | ILAR Journal |
| ISSN: | 1930-6180 1084-2020 |
| Popis: | It is well understood that the biopharmaceutical industry must improve efficiency along the path from laboratory concept to commercial product. In vivo imaging is recognized as a useful method to provide biomarkers for target engagement, treatment response, safety, and mechanism of action. Imaging biomarkers have the potential to inform the selection of drugs that are more likely to be safe and effective. Most of the imaging modalities for biopharmaceutical research are translatable to the clinic. In vivo imaging does not require removal of tissue to provide biomarkers, thus reducing the number of valuable preclinical subjects required for a study. Longitudinal imaging allows for quantitative intra-subject comparisons, enhancing statistical power, and further reducing the number of subjects needed for the evaluation of treatment effects in animal models. The noninvasive nature of in vivo imaging also provides a valuable approach to alleviate or minimize potential pain, suffering or distress. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|